Dr Reddy reports FDA observations: what it means for Dr Reddy stock

Published on 10/09/2026 at 12:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The FTO-11 inspection produced two FDA observations. For Dr Reddy stock, Q1 profit fell 69.00 percent before results on October 23, 2026.

Key points in brief

Dr. Reddy's Laboratories disclosed two FDA observations at its FTO-11 facility after an inspection from October 5 to October 7, 2026.
The company will publish results for the quarter and six months ended September 30, 2026, on October 23, 2026.
Q1 FY27 revenue fell 5.60 percent to INR 80.705 billion, while net profit declined 69.00 percent to INR 4.43 billion.
The NYSE-listed ADR was USD 12.20 on October 8, 2026, with a 52-week range of USD 11.36 to USD 15.67.

Dr Reddy, INE089A01023, Illustration mit AI erstellt.

Dr. Reddy's Laboratories (INE089A01023) disclosed two FDA observations at its FTO-11 manufacturing facility after an inspection from October 5 to October 7, 2026, according to Business Today on October 9, 2026. The same disclosure set October 23, 2026, for the release of results covering the quarter and six months ended September 30, 2026.

Three dates shape the setup

On March 21, 2026, Dr. Reddy's announced India's first DCGI-approved semaglutide injection, Obeda, according to GreekSoup. On July 23, 2026, a Motilal Oswal update described first-quarter fiscal 2027 revenue of INR 80.9 billion and a Neutral rating, according to DSIJ.

On October 7, 2026, the FDA inspection at FTO-11 ended with two observations, while the company scheduled its next results release for October 23, 2026. That sequence puts regulatory execution and the September-quarter numbers on the same timetable.

What does the FDA update mean for margins

The latest reported quarter shows why the inspection matters. Revenue from operations fell 5.60 percent to INR 80.705 billion in the April to June 2026 quarter from INR 85.452 billion a year earlier, while consolidated net profit dropped 69.00 percent to INR 4.43 billion from INR 14.18 billion, according to Business Today. The quarter also included an INR 2.40 billion provision for inventory and related costs linked to semaglutide supply disruption.

DSIJ reported that Motilal Oswal expected commercial semaglutide supply to resume by November 2026 and listed an INR 2.40 billion provision for affected inventory and associated costs. The broker's July 23, 2026, target was INR 1,125, based on 20 times 12-month forward earnings, making the October results a test of whether supply recovery can offset lower North American sales.

Next dates and market context

The next disclosed reporting date is October 23, 2026, for the September-quarter and half-year results. DSIJ also cited mid-December 2026 as the USFDA goal date for the b-Abatacept program, giving investors a second dated regulatory milestone.

The NYSE-listed ADR was last at USD 12.20 on October 8, 2026, at 4:00 p.m. ET, against a prior close of USD 12.27. Its 52-week range was USD 11.36 to USD 15.67 on the same quote snapshot, leaving the ADR USD 3.47 below its high. The further course of trading is shown by the continuously updated real-time quote of Dr Reddy stock.